Janssen Pharmaceuticals Inc., of Titusville, N.J., a unit of Johnson & Johnson, said it submitted a supplemental new drug application for once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate) to the FDA for approval to treat schizoaffective disorder as either monotherapy or adjunctive therapy.